Research Article
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
Table 3
Therapy of 124 TNBC patients assessed for BRCA1/2 mutations.
| Type of therapy | Patients tested for BRCA mutations | value (BRCA-positive vs BRCA-negative) | BRCA noncarriers | Rate (%) | BRCA carriers | Rate (%) |
| Number of patients | 94 | 100 | 30 | 100 | |
| Surgery | Yes | 90 | 96 | 29 | 97 | 0.7004 | No | 4 | 4 | 1 | 3 |
| Type of surgery | Mastectomy | 60/90 | 66.5 | 17/29 | 58.5 | 0.2438 | Breast-conserving surgery | 30/90 | 33.5 | 12/29 | 41.5 |
| Radiotherapy | Yes | 55 | 58.5 | 17 | 56.5 | 0.7751 | No | 39 | 41.5 | 13 | 43.5 |
| Radiotherapy | After mastectomy | 27/55 | 49 | 5/17 | 29.5 | 0.0044 | After breast-conserving surgery | 28/55 | 51 | 12/17 | 70.5 |
| Neoadjuvant chemotherapy | Yes | 20 | 21.5 | 4 | 13.5 | 0.0940 | No | 74 | 78.5 | 26 | 86.5 |
| Regimens in neoadjuvant chemotherapy | AT⟶CMF | 5/20 | 25 | 1/4 | 25 | <0.0001 | Anthracycline + taxane | 9/20 | 45 | 2/4 | 50 | Anthracycline | 5/20 | 5 | 1/4 | 25 | Others | 1/20 | 25 | 0 | 0 |
| Adjuvant chemotherapy | Yes | 64 | 68 | 23 | 76.5 | 0.1541 | No | 30 | 32 | 7 | 23.5 |
| Regimens in adjuvant chemotherapy | Anthracycline (AC) | 41/64 | 64 | 12/23 | 52 | 0.0574 | FEC/FAC | 11/64 | 17.5 | 4/23 | 17.5 | Anthracycline + taxane | 8/64 | 12.5 | 5/23 | 21.5 | CMF | 2/64 | 3 | 0 | 0 | Taxane | 2/64 | 3 | 2/23 | 9 |
|
|